


DEC 11 2007

Docket No.: EISN-018CP

Application No.: 10/657,910

AMENDMENTS TO THE CLAIMS

1. (currently amended) A pharmaceutical composition for systemic administration comprising a pharmaceutically suitable carrier or diluent and a compound having the structure:



or pharmaceutically acceptable salt or ester derivative thereof; wherein

R<sub>1</sub> is hydrogen, C<sub>1</sub>-C<sub>20</sub> alkyl, C<sub>2</sub>-C<sub>20</sub> alkenyl, C<sub>2</sub>-C<sub>20</sub> alkynyl, C<sub>1</sub>-C<sub>20</sub> heteroalkyl, C<sub>2</sub>-C<sub>20</sub> heteroalkenyl, C<sub>2</sub>-C<sub>20</sub> heteroalkynyl, C<sub>3</sub>-C<sub>20</sub> cycloalkyl, C<sub>3</sub>-C<sub>20</sub> cycloalkenyl, C<sub>3</sub>-C<sub>20</sub> cycloalkynyl, C<sub>3</sub>-C<sub>20</sub> heterocycloalkyl, C<sub>3</sub>-C<sub>20</sub> heterocycloalkenyl, C<sub>3</sub>-C<sub>20</sub> heterocycloalkynyl, aliphatic, heteroaliphatic, alicyclic, heteroalicyclic, C<sub>3</sub>-C<sub>14</sub> aryl or C<sub>3</sub>-C<sub>14</sub> heteroaryl;

R<sub>2</sub> is methyl;

R<sub>3</sub> is hydrogen, halogen, hydroxyl, protected hydroxyl, or a C<sub>1</sub>-C<sub>20</sub> alkyl, C<sub>2</sub>-C<sub>20</sub> alkenyl, C<sub>2</sub>-C<sub>20</sub> alkynyl, C<sub>1</sub>-C<sub>20</sub> heteroalkyl, C<sub>2</sub>-C<sub>20</sub> heteroalkenyl, C<sub>2</sub>-C<sub>20</sub> heteroalkynyl, C<sub>3</sub>-C<sub>20</sub> cycloalkyl, C<sub>3</sub>-C<sub>20</sub> cycloalkenyl, C<sub>3</sub>-C<sub>20</sub> cycloalkynyl, C<sub>3</sub>-C<sub>20</sub> heterocycloalkyl, C<sub>3</sub>-C<sub>20</sub> heterocycloalkenyl, C<sub>3</sub>-C<sub>20</sub> heterocycloalkynyl, an aliphatic, heteroaliphatic, alicyclic, heteroalicyclic, C<sub>3</sub>-C<sub>14</sub> aryl or C<sub>3</sub>-C<sub>14</sub> heteroaryl moiety; or

R<sub>1</sub> and R<sub>3</sub>, when taken together, may form a substituted or unsubstituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;

R<sub>4</sub> is hydrogen or halogen;

R<sub>5</sub> is hydrogen or an oxygen protecting group;

R<sub>6</sub> is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R<sub>7</sub>, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

Application No.: 10/657,910

Docket No.: EISN-018CP

$R_8$  is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or a  $C_1$ - $C_{20}$  alkyl,  $C_2$ - $C_{20}$  alkenyl or  $C_2$ - $C_{20}$  alkynyl ~~an aliphatic~~ moiety optionally substituted with hydroxyl, protected hydroxyl,  $SR_{12}$ , or  $NR_{12}R_{13}$ ;

$R_9$  is hydrogen, halogen, hydroxyl, protected hydroxyl,  $OR_{12}$ ,  $SR_{12}$ ,  $NR_{12}R_{13}$ ,  $-X_1(CH_2)_pX_2-R_{14}$ , or is lower alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or  $-X_1(CH_2)_pX_2-R_{14}$ ;

wherein  $R_{12}$  and  $R_{13}$  are, independently for each occurrence, hydrogen,  $C_1$ - $C_{20}$  alkyl,  $C_2$ - $C_{20}$  alkenyl,  $C_2$ - $C_{20}$  alkynyl,  $C_1$ - $C_{20}$  heteroalkyl,  $C_2$ - $C_{20}$  heteroalkenyl,  $C_2$ - $C_{20}$  heteroalkynyl,  $C_3$ - $C_{20}$  cycloalkyl,  $C_3$ - $C_{20}$  cycloalkenyl,  $C_3$ - $C_{20}$  cycloalkynyl,  $C_3$ - $C_{20}$  heterocycloalkyl,  $C_3$ - $C_{20}$  heterocycloalkenyl,  $C_3$ - $C_{20}$  heterocycloalkynyl, ~~aliphatic, heteroaliphatic, alicyclic, heteroalicyclic,~~  $C_3$ - $C_{14}$  aryl or  $C_3$ - $C_{14}$  heteroaryl; or a nitrogen or oxygen protecting group, or  $R_{12}$  and  $R_{13}$ , taken together may form a saturated or unsaturated cyclic ring of containing-1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms, and each of  $R_{12}$  and  $R_{13}$  are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,

wherein  $X_1$  and  $X_2$  are each independently absent, or are oxygen, NH, or  $-N(\text{alkyl})$ , or wherein  $X_2-R_{14}$  together are  $N_3$  or are a saturated or unsaturated heterocyclic moiety,

$p$  is 2-10, and

$R_{14}$  is hydrogen, or an  $C_3$ - $C_{14}$  aryl,  $C_3$ - $C_{14}$  heteroaryl,  $C_1$ - $C_{20}$  alkyl( $C_3$ - $C_{14}$ )aryl, or  $C_1$ - $C_{20}$  alkyl( $C_3$ - $C_{14}$ )heteroaryl moiety, or is  $-(C=O)NHR_{15}$ ,  $-(C=O)OR_{15}$ , or  $-(C=O)R_{15}$ , wherein each occurrence of  $R_{15}$  is independently hydrogen,  $C_1$ - $C_{20}$  alkyl,  $C_2$ - $C_{20}$  alkenyl,  $C_2$ - $C_{20}$  alkynyl,  $C_1$ - $C_{20}$  heteroalkyl,  $C_2$ - $C_{20}$  heteroalkenyl,  $C_2$ - $C_{20}$  heteroalkynyl,  $C_3$ - $C_{20}$  cycloalkyl,  $C_3$ - $C_{20}$  cycloalkenyl,  $C_3$ - $C_{20}$  cycloalkynyl,  $C_3$ - $C_{20}$  heterocycloalkyl,  $C_3$ - $C_{20}$  heterocycloalkenyl,  $C_3$ - $C_{20}$  heterocycloalkynyl, ~~aliphatic, heteroaliphatic, alicyclic, heteroalicyclic,~~  $C_3$ - $C_{14}$  aryl or  $C_3$ - $C_{14}$  heteroaryl; or  $R_{14}$  is  $-SO_2(R_{16})$ , wherein  $R_{16}$  is a  $C_1$ - $C_{20}$  alkyl,  $C_2$ - $C_{20}$  alkenyl or  $C_2$ - $C_{20}$  alkynyl ~~an aliphatic~~ moiety, wherein one or more of  $R_{14}$ ,  $R_{15}$ , or  $R_{16}$  are optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen; or

Application No.: 10/657,910

Docket No.: EISN-018CP

$R_8$  and  $R_9$  may, when taken together, form a saturated or unsaturated cyclic ring of ~~containing~~ 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;

$R_{10}$  is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;

$R_{11}$  is hydrogen, hydroxyl or protected hydroxyl;

X is O, ~~NH~~, or ~~CH<sub>2</sub>~~;

Y is  $\text{CHR}_{17}$ ,  $\Theta$ ,  $\text{C}=\text{O}$ , or  $\text{CR}_{17}$  ~~or~~  $\text{NR}_{17}$ ; and Z is  $\text{CHR}_{18}$ ,  $\Theta$ ,  $\text{C}=\text{O}$ , or  $\text{CR}_{18}$  ~~or~~  $\text{NR}_{18}$ ,

wherein each occurrence of  $R_{17}$  and  $R_{18}$  is independently hydrogen,  $\text{C}_1\text{-C}_{20}$  alkyl,  $\text{C}_2\text{-C}_{20}$  alkenyl or  $\text{C}_2\text{-C}_{20}$  alkynyl ~~or aliphatic, or  $R_{17}$  and  $R_{18}$  taken together is O,  $\text{CH}_2$  or  $\text{NR}_{17}$~~ , wherein  $R_{17}$  is hydrogen or lower alkyl, and Y and Z may be connected by a single or double bond;

wherein oxygen protecting groups are selected from the group consisting of methyl ethers, substituted methyl ethers, methoxymethyl ether, methylthiomethyl ether, benzyloxymethyl ether, p-methoxybenzyloxymethyl ether, substituted ethyl ethers, substituted benzyl ethers, silyl ethers, trimethylsilyl ether, triethylsilyl ether, triisopropylsilyl ether, t-butyl dimethylsilyl ether, tribenzyl silyl ether, t-butyl diphenyl silyl ether, esters, formate, acetate, benzoate, trifluoroacetate, dichloroacetate, carbonates, cyclic acetals and ketals and wherein nitrogen protecting groups are selected from the group consisting of carbamates, Troc, amides, cyclic imides, N-alkyl amines, N-aryl amines, imines, and enamines;

wherein the compound is present in an amount effective to inhibit production of a pro-inflammatory and/or immunologic cytokine.

2. (currently amended) The composition of claim 1, wherein:

$R_1$  is hydrogen, straight or branched lower alkyl, straight or branched lower heteroalkyl, or  $\text{C}_3\text{-C}_{14}$  aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

$R_2$  is methyl;

$R_3$  is hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched lower alkyl, straight or branched lower heteroalkyl, or  $\text{C}_3\text{-C}_{14}$  aryl,

Application No.: 10/657,910

Docket No.: EISN-018CP

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or  $R_1$  and  $R_3$ , when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;  $R_4$  is hydrogen or halogen;  $R_5$  is hydrogen or a protecting group;  $R_6$  is hydrogen, hydroxyl, or protected hydroxyl;  $n$  is 0-2;  $R_7$ , for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;  $R_8$  is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or lower alkyl optionally substituted with hydroxyl, protected hydroxyl,  $SR_{12}$ , or  $NR_{12}R_{13}$ ;  $R_9$  is hydrogen, halogen, hydroxyl, protected hydroxyl,  $OR_{12}$ ,  $SR_{12}$ ,  $NR_{12}R_{13}$ ,  $-X_1(CH_2)_pX_2-R_{14}$ , or is lower alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or  $-X_1(CH_2)_pX_2-R_{14}$ ;

wherein  $R_{12}$  and  $R_{13}$  are, independently for each occurrence, hydrogen, lower alkyl,  $C_3-C_{14}$  aryl,  $C_3-C_{14}$  heteroaryl, alkyl( $C_3-C_{14}$ )aryl, or alkyl( $C_3-C_{14}$ )heteroaryl, or a nitrogen or oxygen protecting group, or  $R_{12}$  and  $R_{13}$ , taken together may form a saturated or unsaturated cyclic ring ~~of containing~~ 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms, and each of  $R_{12}$  and  $R_{13}$  are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen, wherein  $X_1$  and  $X_2$  are each independently absent, or are oxygen, NH, or  $-N(\text{alkyl})$ , or wherein  $X_2-R_{14}$  together are  $N_3$  or are a saturated or unsaturated heterocyclic moiety,  $p$  is 2-10, and

$R_{14}$  is hydrogen, or ~~an~~  $C_3-C_{14}$  aryl,  $C_3-C_{14}$  heteroaryl, alkyl( $C_3-C_{14}$ )aryl, or alkyl( $C_3-C_{14}$ )heteroaryl moiety, or is  $-(C=O)NHR_{15}$ ,  $-(C=O)OR_{15}$ , or  $-(C=O)R_{15}$ , wherein each occurrence of  $R_{15}$  is independently hydrogen, alkyl, heteroalkyl,  $C_3-C_{14}$  aryl,  $C_3-C_{14}$  heteroaryl, alkyl( $C_3-C_{14}$ )aryl, or alkyl( $C_3-C_{14}$ )heteroaryl, or  $R_{14}$  is  $-SO_2(R_{16})$ , wherein  $R_{16}$  is an alkyl moiety, wherein one or more of  $R_{14}$ ,  $R_{15}$ , or  $R_{16}$  are optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen; or

Application No.: 10/657,910

Docket No.: EISN-018CP

$R_8$  and  $R_9$  may, when taken together, form a saturated or unsaturated cyclic ring of ~~containing~~ 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;


$R_{10}$  is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;

$R_{11}$  is hydrogen, hydroxyl or protected hydroxyl;

X is O;

Y is  $\text{CHR}_{17}$ ,  $\text{O}$ ,  $\text{C}=\text{O}$ , or  $\text{CR}_{17}$  or  $\text{NR}_{17}$ ; and Z is  $\text{CHR}_{18}$ ,  $\text{O}$ ,  $\text{C}=\text{O}$ , or  $\text{CR}_{18}$  or  $\text{NR}_{18}$ , wherein each occurrence of  $R_{17}$  and  $R_{18}$  is independently hydrogen or lower alkyl, or  $R_{17}$  and  $R_{18}$  taken together is  $\text{O}$ ,  $\text{CH}_2$  or  $\text{NR}_{19}$ , wherein  $R_{19}$  is hydrogen or lower alkyl, and Y and Z may be connected by a single or double bond.

3. (previously presented) The composition of claim 2, where n is 1.
4. (original) The composition of claim 2, where  $R_4$  is halogen.
5. (original) The composition of claim 2, where  $R_4$  is fluorine.
6. (original) The composition of claim 2, where Y and Z together represent  $\text{CH}=\text{CH}$ .
7. (original) The composition of claim 2, where Y and Z together represent trans  $\text{CH}=\text{CH}$ .
8. (previously presented) The composition of claim 2, wherein  $R_1$  and  $R_2$  are each methyl and  $R_3$  is hydrogen and the compound has the structure:




wherein  $R_4$ - $R_{11}$ , n, Y and Z are as defined in claim 2.

9. (previously presented) The composition of claim 8, wherein n is 1.

**Application No.: 10/657,910**

**Docket No.: EISN-018CP**

10. (original) The composition of claim 8, wherein R<sub>4</sub> is halogen.
11. (original) The composition of claim 8, wherein Y and Z together represent -CH=CH-.
12. (previously presented) The composition of claim 8, wherein n is 1, R<sub>4</sub> is halogen and Y and Z together represent -CH=CH-.
13. (original) The composition of claim 11 or 12 wherein -CH=CH- is trans.
14. (currently amended) The composition of claim 2, wherein R<sub>9</sub> is NR<sub>12</sub>R<sub>13</sub> and the compound has the structure:



wherein R<sub>1</sub>-R<sub>13</sub>, n, Y and Z are as defined in claim 2, or


R<sub>13</sub> and R<sub>8</sub> may, when taken together, form a cyclic ring of containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydrogen, alkyloxy, amino, alkylamino, aminoalkyl, and halogen.

15. (previously presented) The composition of claim 14, wherein n is 1.
16. (original) The composition of claim 14, wherein R<sub>4</sub> is halogen.
17. (original) The composition of claim 14, wherein Y and Z together represent -CH=CH-.
18. (original) The composition of claim 14, wherein R<sub>1</sub> and R<sub>2</sub> are each methyl and R<sub>3</sub> is hydrogen.
19. (previously presented) The composition of claim 14, wherein n is 1, R<sub>1</sub> and R<sub>2</sub> are each methyl, R<sub>3</sub> is hydrogen, R<sub>4</sub> is halogen, and Y and Z together represent -CH=CH-.

Application No.: 10/657,910


Docket No.: EISN-018CP

20. (original) The composition of claim 17 or 19, wherein  $-\text{CH}=\text{CH}-$  is trans.
21. (original) The composition of claim 1 wherein the compound has the structure:




or pharmaceutically acceptable salt or ester derivative thereof.

22. (original) The composition of claim 1 wherein the compound has the structure:



or pharmaceutically acceptable salt or ester derivative thereof.

23. (original) The composition of claim 1 wherein the compound has the structure:




or pharmaceutically acceptable salt or ester derivative thereof.

24. (original) The composition of claim 1 wherein the compound has the structure:


Application No.: 10/657,910

Docket No.: EISN-018CP


or pharmaceutically acceptable salt or ester derivative thereof.

25-26. (canceled)

27. (original) The composition of claim 1 wherein the compound has the structure:

or pharmaceutically acceptable salt or ester derivative thereof.

28. (original) The composition of claim 1 wherein the compound has the structure:


or pharmaceutically acceptable salt or ester derivative thereof.

29. (original) The composition of claim 1 wherein the compound has the structure:




Application No.: 10/657,910


Docket No.: B1SN-018CP

or pharmaceutically acceptable salt or ester derivative thereof.

30. (original) The composition of claim 1 wherein the compound has the structure:

or pharmaceutically acceptable salt or ester derivative thereof.

31. (original) The composition of claim 1 wherein the compound has the structure:


or pharmaceutically acceptable salt or ester derivative thereof.

32. (canceled)

33. The composition of claim 1 wherein the compound has the structure:

Application No.: 10/657,910

Docket No.: EISN-018CP



or pharmaceutically acceptable salt or ester derivative thereof.

34-35. (canceled)

36. (withdrawn) The pharmaceutical composition of claim 1, wherein the composition is for oral administration.

37. (canceled)

38. (withdrawn) The pharmaceutical composition of claim 1, wherein the pro-inflammatory and/or immunologic cytokine is  $\text{TNF}\alpha$ , IL-1, IL-6, IL-8 or IL-2.

39. (withdrawn) A method for treating rheumatoid arthritis, psoriasis, asthma, sepsis, inflammatory bowel disease, atopic dermatitis or Crohn's disease comprising the step of systemically administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 1.

40. (withdrawn) The method of claim 39, wherein the compound is administered orally.


41. (canceled)

42. (withdrawn) The method of claim 39, wherein the method is for treating psoriasis.

43. (withdrawn, currently amended) The method of claim 39-41, wherein the compound has any one of the following structures:


Application No.: 10/657,910

Docket No.: EISN-018CP



Application No.: 10/657,910

Docket No.: EISN-018CP



or pharmaceutically acceptable salt or ester derivative thereof.


44. (canceled)
45. (withdrawn) The method of claim 39, wherein the pro-inflammatory and/or immunologic cytokine is TNF $\alpha$ , IL-1, IL-6, IL-8 or IL-2.
46. (withdrawn) The composition of claim 2, where R<sub>1</sub> is hydrogen or methyl.
47. (withdrawn) The composition of claim 2, where R<sub>3</sub> is hydrogen or halogen.
48. (withdrawn) The composition of claim 2, where R<sub>4</sub> is hydrogen.
49. (withdrawn) The composition of claim 2, where R<sub>5</sub> is hydrogen.
50. (withdrawn) The composition of claim 2, where R<sub>6</sub> is hydroxyl.

Application No.: 10/657,910


Docket No.: EISN-018CP

51. (withdrawn) The composition of claim 2, where  $R_7$  is hydrogen or hydroxyl.
52. (withdrawn) The composition of claim 2, where  $R_8$  is hydrogen or halogen.
53. (withdrawn) The composition of claim 2, where  $R_9$  is hydroxyl, protected hydroxyl, -OR<sub>12</sub>, -NR<sub>12</sub>R<sub>13</sub>, or -O(CH<sub>2</sub>)<sub>p</sub>X<sub>2</sub>-R<sub>14</sub>, wherein R<sub>12</sub>, R<sub>13</sub>, R<sub>14</sub> and X<sub>2</sub> are as defined in claim 2.

54. (withdrawn) The composition of claim 53, where  $R_9$  is -OR<sub>12</sub>, wherein R<sub>12</sub> is methyl, ethyl, propyl, isopropyl, butyl, -CH<sub>2</sub>COOMe, Bn, PMB (MPM), 3,4-CIBn, or  $R_9$  is



55. (withdrawn) The composition of claim 53, where  $R_9$  is -NR<sub>12</sub>R<sub>13</sub>, or wherein R<sub>12</sub> is methyl, ethyl, propyl, isopropyl, or butyl, optionally substituted with one or more occurrences of hydroxyl or protected hydroxyl, and R<sub>13</sub> is hydrogen or lower alkyl, or NR<sub>12</sub>R<sub>13</sub> together represents a 5- or 6- membered heterocyclic moiety.
56. (withdrawn) The composition of claim 53, where  $R_9$  is -O(CH<sub>2</sub>)<sub>p</sub>X<sub>2</sub>-R<sub>14</sub>, wherein X<sub>2</sub>-R<sub>14</sub> together represent N<sub>3</sub>, NMe<sub>2</sub>, NHAc, NHSO<sub>2</sub>Me, NHCONHMe, NHCONHPh, morpholine, imidazole, aminopyridine, or any one of:




57. (withdrawn, currently amended) The composition of claim 2, where  $R_8$  and  $R_9$ , taken together, form a saturated or unsaturated cyclic ring of containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl,

Application No.: 10/657,910

Docket No.: EISN-018CP


protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen.

58. (withdrawn) The composition of claim 2, where  $R_{10}$  is hydroxyl.
59. (withdrawn) The composition of claim 2, where  $R_{11}$  is hydrogen.
60. (withdrawn) The composition of claim 2, where Y and Z together are cyclopropyl.
61. (canceled)
62. (previously presented) The composition of claim 1 wherein the compound has the structure:



or pharmaceutically acceptable salt or ester derivative thereof.

63. (previously presented) The composition of claim 1 wherein the compound has the structure:




or pharmaceutically acceptable salt or ester derivative thereof.

64. (canceled)

Application No.: 10/657,910


Docket No.: EISN-018CP

65. (previously presented) The composition of claim 1 wherein the compound has the structure:



or pharmaceutically acceptable salt or ester derivative thereof.

66. (previously presented) The composition of claim 1 wherein the compound has the structure:



or pharmaceutically acceptable salt or ester derivative thereof.